MedTrace Logo

Measurement of Beta Cell Death in Individuals With Cystic Fibrosis

NCT03713437 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2026-04-07

No results posted yet for this study

Summary

This study evaluates the feasibility of using differentially methylated insulin DNA, a biomarker of beta cell death, in determining the time course of beta cell death and development of diabetes in people with cystic fibrosis. Study participants with cystic fibrosis and healthy control participants will have a blood sample drawn in order to measure the levels of differentially methylated insulin DNA.

Conditions

  • Cystic Fibrosis-related Diabetes

Interventions

DIAGNOSTIC_TEST

Measurement of differentially methylated insulin DNA

A serum sample will be drawn to measure differentially methylated insulin DNA.

Sponsors & Collaborators

  • Cystic Fibrosis Foundation

    collaborator OTHER

  • University of Nebraska

    lead OTHER

Principal Investigators

  • Ashley R Deschamp, MD · University of Nebraska

Eligibility

Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-04
Primary Completion
2021-06-30
Completion
2021-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03713437 on ClinicalTrials.gov